In our weekly Trends that Matter series, we provide engaging infographics, articles and recent news from healthcare influencers to highlight general trends affecting the pharmaceutical industry. In honor of Psoriasis Awareness Month, this week's featured topic is the state of psoriasis treatment.
In today's landscape, there are many safe and effective treatment options available for individuals with psoriasis and psoriatic arthritis. Disease-modifying antirheumatic drugs (DMARDs) can relieve severe symptoms and attempt to slow progression with psoriatic arthritis.
However, surveys conducted by National Psoriasis Foundation indicated that many patients are dissatisfied with their treatment or not using the correct level. To overcome this challenge, patients and healthcare professionals must work together to set specific health goals.
Furthermore, "Efforts in advocacy and education are necessary to ensure that effective treatments are accessible to this patient population," according to researchers from the Department of Dermatology at the University of California-Davis.
To learn more about this topic, download MMIT's Reality Check on Disease Modifying Agents. In this report, expert take a deeper look into the clinical characteristics, drug market access, payer coverage and summarizes key findings within DMARDs.